Hsa-miR-4730 as a new and potential diagnostic and prognostic indicators for pancreatic cancer

Pancreatic cancer is a gastrointestinal tumor with the highest malignancy and few diagnostic and prognostic markers. Patients with disease have a 5-year survival rate that is not more than 10%. As a research hotspot in recent years, miRs (microRNAs) are differentially expressed in various tumors, so they can be used as the potential diagnostic and prognostic markers. In this study, differentially expressed miRs in patients with pancreatic cancer were screened out through the GEO chip, to provide potential markers for clinical practice. This study aimed to explore the expression and potential value of miR-4730 in pancreatic cancer.

Differentially expressed miRs in pancreatic cancer were analyzed through logging in GEO DataSets to download GSE112264. Fifty patients with pancreatic cancer who were treated in our hospital from May 2012 to January 2014 (Group A), 50 patients with benign pancreatic lesions during the same period (Group B), and 50 healthy individuals undergoing physical examinations (Group C) were enrolled in this study. The expression of miR-4730 in the serum and the cancer tissue was detected by qRT-PCR. The correlation of miR-4730 with pathological data, and the diagnostic values of differential indicators in the data were analyzed. The patients were followed up for 5 years to observe the relationship between miR-4730 and their survival.

The analysis of the GEO chip showed 305 differentially expressed miRs, among which 225 were highly expressed and 80 were lowly expressed, with miR-4730 differentially expressed most. The expression of serum miR-4730 in Group A was significantly lower than that in Groups B and C (p<0.05), so miR-4730 had a diagnostic value. The expression of miR-4730 in the cancer tissue was significantly lower than that in the adjacent tissue. The correlation analysis showed that the expression of miR-4730 in the cancer tissue was positively correlated with that in the serum. Patients with low miR-4730 expression had poorly differentiated pancreatic cancer, and patients with stages III+IV of pancreatic cancer had higher incidences of lymphatic invasion and distal metastasis (p<0.05), so miR-4730 had a diagnostic value. The 3- and 5-year survival rates in the high miR-4730 expression group were higher than those in the low expression group (both p<0.05). TNM staging, lymphatic invasion, distal metastasis, and miR-4730 were independent prognostic factors for the 3- and 5-year survival of patients with pancreatic cancer.

For patients with pancreatic cancer, those with low miR-4730 expression have poor survival and prognoses, so miR-4730 can be used as a potential observational index for the prognosis and diagnosis of the disease.